Amgen Sued for Parkinson’s Drug
According to media reports Tuesday, two patients afflicted with Parkinson’s Disease and involved in a clinical trial for an Amgen drug treating the disease have sued Amgen over the discontinuation of the trial.
CellGenix Introduces New Line of Research-grade Cytokines at ISCT 2005
CellGenix is pleased to announce at this year’s ISCT Annual Meeting the introduction of a new line of research grade cytokines for dendritic cell maturation and expansion of progenitor and hematopoietic stem cells.
Dataworks Development Breaks New Ground with the Release of Freezerworks Unlimited 2.0
Dendreon Announces D9901 Phase 3 Study Results for Provenge Immunotherapy to be Presented at ASCO
Endocyte Moves Operations to Purdue Technology Center; Celebrates Anchor Position
Endocyte Inc. today (Thursday, April 28) held an open house to showcase its new, state-of-the-art facilities in the Purdue Research Park’s newly expanded flagship incubator.
FDA Approves Baxter’s GAMMAGARD Liquid 10% for Patients with Primary Immunodeficiency Disorders
Baxter Healthcare Corporation announced today that the U. S. Food and Drug Administration (FDA) has approved GAMMAGARD ® Liquid [Immune Globulin Intravenous (Human)] (IGIV) 10% Solution for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity.
Genetic Mingling Mixes Human, Animal Cells
On a farm about six miles outside this gambling town, Jason Chamberlain looks over a flock of about 50 smelly sheep, many of them possessing partially human livers, hearts, brains and other organs.
ImmunoGen, Inc. Announces Genentech’s Renewal of Technology Access Agreement
MaxCyte Appoints Ronald Holtz and Madhusudan Peshwa to Executive Team
Neurologix and Medtronic Agree to Develop Gene Therapy Infusion Catheters; Medtronic Makes a Further $2 Million Equity Investment in Neurologix
Neurologix, Inc., which through its subsidiary Neurologix Research, Inc., is engaged in the research and development of proprietary treatments for disorders of the brain and central nervous system (CNS) primarily utilizing gene therapies, announced it has entered into an agreement with Medtronic, Inc. for the joint development, manufacturing and commercialization of micro-infusion catheters designed to deliver gene therapy into the brain and central nervous system.
Origen Releases New Polymer for Use in Cryogenic Preservation
Origen Biomedical announced today the release of a new polymer for cryogenic use. A derivation of Olefins and Vinyl acetates, this material, along with FEP are the only two known polymer materials which do not exhibit a defined glass transition point down to -196C.
Peter MacCallum Cancer Centre Announces Formation of Dedicated Business Unit to Manage cGMP Cell Processing Facility
The Peter MacCallum Cancer Centre and its Centre for Blood Cell Therapies (CBCT) have, for some time, been undertaking fee-based clinical trials involving cell and tissue manipulation under cGMP and regulated manufacturing conditions.
PharmaFrontiers Selects INC Research as Development Partner for its Novel Multiple Sclerosis Therapy
PharmaFrontiers Corp., a biotechnology company developing autologous cellular therapies for the treatment of multiple sclerosis, congestive heart failure, and diabetes, and INC Research, Inc.(R), a global contract research organization (CRO) specialized in central nervous system (CNS), oncology, and pediatric clinical research, today announced that they have formed a strategic relationship to develop multiple sclerosis therapies.
Regenetech Announces Adult Stem Cells Safe
Regenetech Inc., a Houston-based, adult-stem-cell company, said today recent studies of adult stem cells expanded with its NASA-created techniques indicate the cells do not turn cancerous.
Seattle Genetics Launches Manufacturing Campaign with Albany Molecular Research
Seattle Genetics, Inc. announced today that it has entered into an agreement with Albany Molecular Research, Inc. for cGMP manufacturing of the proprietary drug-linker system employed in its SGN-35 product candidate.
Seattle Genetics Receives U.S. Patent Relating to Its Antibody-Drug Conjugate Technology
Seattle Genetics, Inc. announced today that it has received a patent issued by the U.S. Patent and Trademark Office (USPTO) relating to the company’s antibody-drug conjugate (ADC) technology.
StemCell Technologies Highlights Several New Products in 2005/2006 Catalog: New Catalog Available at ISCT 2005 Conference
Velcade® (Borezomib) for Injection Receives European Marketing Authorisation for Second-line Use in Multiple Myeloma Patients
Expanded label for VELCADE®, the only approved drug therapy to offer a significant survival advantage in relapsed multiple myeloma.
VIRxSYS Announces Completion of Phase I study of VRX496, Novel HIV Gene Therapy, and Plans to Initiate Phase II Study
VIRxSYS Corporation, a private biotechnology company focused on the development of gene therapy treatments for diseases such as HIV/AIDS, reports completion of the initial protocol-mandated observations in a Phase I clinical trial evaluating the safety and tolerability of the novel HIV gene therapy VRX496.
Malachite Management has joined forces with established and reputable authors and publishers to bring you the following market reports outlining the very latest in Cell Therapy, Gene Therapy, and Immunotherapeutic approaches to Cancer.
“Cell Therapy – Technologies, Markets, and Companies” is over 400 pages of the basic technologies, clinical applications, market analysis, and company profiles related to the cell therapy industry worldwide.
For more information, including order forms, please see:
Cell Therapy Report Summary
Cell Therapy Sample Chapter
Cell Therapy Table of Contents Vol. 1 Vol. 2
Cell Therapy Order Form
“Gene Therapy – Technologies, Markets, and Companies” is over 500 pages of the basic technologies, clinical applications, market analysis, and company profiles related to the gene therapy industry worldwide.
For more information, including order forms, please see:
Gene Therapy Report Summary
Gene Therapy Table of Contents Vol. 1 Vol. 2
Gene Therapy Order Form
The Immunotherapy Reports cover the most recent developments in the immunotherapeutic approaches to cancer.
A Shift in Cancer Immunotherapy Strategies?
Immunotherapy Strategies Executive Summary
Immunotherapy Strategies Table of Contents
Future Perspectives in Cancer Immunotherapy
Future Perspectives Executive Summary
Future Perspectives Table of Contents
Immunotherapy Reports Order Form